| K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer CS Karapetis, S Khambata-Ford, DJ Jonker, CJ O'Callaghan, D Tu, ... New England Journal of Medicine 359 (17), 1757-1765, 2008 | 4466 | 2008 |
| Cetuximab for the treatment of colorectal cancer DJ Jonker, CJ O'Callaghan, CS Karapetis, JR Zalcberg, D Tu, HJ Au, ... New England Journal of Medicine 357 (20), 2040-2048, 2007 | 2423 | 2007 |
| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo … CS Fuchs, J Tomasek, CJ Yong, F Dumitru, R Passalacqua, C Goswami, ... The Lancet 383 (9911), 31-39, 2014 | 2362 | 2014 |
| Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial J Verweij, PG Casali, J Zalcberg, A LeCesne, P Reichardt, JY Blay, ... The Lancet 364 (9440), 1127-1134, 2004 | 2094 | 2004 |
| Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis KM Sjoquist, BH Burmeister, BM Smithers, JR Zalcberg, RJ Simes, ... The lancet oncology 12 (7), 681-692, 2011 | 1898 | 2011 |
| Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis V Gebski, B Burmeister, BM Smithers, K Foo, J Zalcberg, J Simes The lancet oncology 8 (3), 226-234, 2007 | 1492 | 2007 |
| NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)—update of the NCCN clinical practice guidelines GD Demetri, RS Benjamin, CD Blanke, JY Blay, P Casali, H Choi, ... Journal of the National Comprehensive Cancer Network 5 (S2), S-1-S-29, 2007 | 1100 | 2007 |
| KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours M Debiec-Rychter, R Sciot, A Le Cesne, M Schlemmer, P Hohenberger, ... European journal of cancer 42 (8), 1093-1103, 2006 | 1064 | 2006 |
| Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation … SY Ngan, B Burmeister, RJ Fisher, M Solomon, D Goldstein, D Joseph, ... J Clin Oncol 30 (31), 3827-33, 2012 | 991 | 2012 |
| Association of KRAS p. G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab W De Roock, DJ Jonker, F Di Nicolantonio, A Sartore-Bianchi, D Tu, ... Jama 304 (16), 1812-1820, 2010 | 877 | 2010 |
| Delivering affordable cancer care in high-income countries R Sullivan, J Peppercorn, K Sikora, J Zalcberg, NJ Meropol, E Amir, ... The lancet oncology 12 (10), 933-980, 2011 | 797 | 2011 |
| Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III … NC Tebbutt, K Wilson, VJ Gebski, MM Cummins, D Zannino, ... | 502 | 2010 |
| Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg JR Zalcberg, J Verweij, PG Casali, A Le Cesne, P Reichardt, JY Blay, ... European Journal of Cancer 41 (12), 1751-1757, 2005 | 497 | 2005 |
| Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO. 17 SY Brulé, DJ Jonker, CS Karapetis, CJ O˘Callaghan, MJ Moore, R Wong, ... European journal of cancer 51 (11), 1405-1414, 2015 | 384 | 2015 |
| A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer JD Mellor, MP Brown, HR Irving, JR Zalcberg, A Dobrovic Journal of hematology & oncology 6, 1-10, 2013 | 369 | 2013 |
| Randomized trial of coordinated psychosocial interventions based on patient self-assessments versus standard care to improve the psychosocial functioning of patients with cancer SA McLachlan, A Allenby, J Matthews, A Wirth, D Kissane, M Bishop, ... Journal of Clinical Oncology 19 (21), 4117-4125, 2001 | 344 | 2001 |
| Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial ND James, MR Spears, NW Clarke, DP Dearnaley, MD Mason, CC Parker, ... JAMA oncology 2 (3), 348-357, 2016 | 319* | 2016 |
| Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial JY Blay, C Serrano, MC Heinrich, J Zalcberg, S Bauer, H Gelderblom, ... The Lancet Oncology 21 (7), 923-934, 2020 | 318 | 2020 |
| Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs EK Baker, RW Johnstone, JR Zalcberg, A El-Osta Oncogene 24 (54), 8061-8075, 2005 | 266 | 2005 |
| Precipitous Release of Methyl-CpG Binding Protein 2 and Histone Deacetylase 1 from the Methylated Human Multidrug Resistance Gene (MDR1) on Activation A El-Osta, P Kantharidis, JR Zalcberg, AP Wolffe Molecular and cellular biology 22 (6), 1844-1857, 2002 | 262 | 2002 |
